GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
603127 Joinn Laboratories
- 15.69
- +0.20+1.29%
Market Closed Jan 24 15:00 CST
11.76BMarket Cap-15690.00P/E (TTM)
15.79High15.37Low49.95KlotVolume15.49Open15.49Pre Close78.08MTurnover0.79%Turnover Ratio29.60P/E (Static)749.48MShares21.7452wk High1.47P/B9.89BFloat Cap12.1652wk Low17.04Limit Up630.48MShs Float92.24Historical High13.94Limit Down2.71%Amplitude1.45Historical Low0.16Dividend TTM15.63Avg Price23.93KlotAsk1.02%Div YieldTTM100Lot Size24.25KlotBid
Joinn Laboratories News
Beijing Zhaoyan New Drug Research Center Co., Ltd. 2024 Annual Results Forecast
JOINN Laboratories Issues Profit Warning for 2024
Express News | Joinn Laboratories China Sees Operating Revenue in 2024 RMB1.92 Bln to RMB2.12 Bln
JOINN: PROFIT WARNINGANNOUNCEMENT ON THE ESTIMATED DECREASEIN ANNUAL RESULTS FOR THE YEAR OF 2024
Joinn Laboratories (603127.SH) expects a net income of 58.688 million to 88.032 million yuan in 2024, a year-on-year decrease of 77.8% to 85.2%.
Joinn Laboratories (603127.SH) announced that it expects to achieve revenue of approximately 191 million yuan in 2024, ...
【Brokerage Focus】CITIC SEC指出今年是在底部布局医疗健康产业优秀赛道和头部核心企业的最佳机会.
Golden Owl Finance | CITIC SEC stated that the 43rd J.P. Morgan Healthcare Conference will be held from January 13 to 16, 2025, in San Francisco, USA. As the largest and most content-rich healthcare investment seminar in the industry, it brings together global industry leaders, rapidly growing emerging companies, innovative technology creators, and investment professionals. According to the exchanges disclosed by participating companies, specifically, in the area of Innovative Drugs, the technological iteration and business development around core products/fields remain the growth engines for Pharma; in the CXO and upstream life sciences sector, upstream research and development needs are showing moderate recovery.
JOINN Laboratories Announces Key Meeting Outcomes and Governance Changes
Joinn Laboratories (06127) appointed Luo Xuan and Gu Jingliang as executive Directors.
Joinn Laboratories (06127) announced the following appointments: (i) Ms. Luo Xuan and Mr. Gu Jingliang as Executive Directors;(...
China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.
In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.
Joinn Laboratories (06127.HK) spent 10.3335 million yuan on January 3 to repurchase 0.6137 million A-shares.
On January 3, 2023, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 613,700 A-shares for 10.3335 million yuan, with a repurchase price of 16.35 to 17.2 yuan per share.
Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Share Price Could Signal Some Risk
Joinn Laboratories (06127) spent 3.282 million yuan on December 31 to repurchase 0.194 million A-shares.
Joinn Laboratories (06127) announced that it will spend 3.282 million yuan to buy back ...
Joinn Laboratories (06127.HK) spent 1.704 million yuan to repurchase 0.1 million A-shares on December 30.
On December 30, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 0.1 million A-shares, costing 1.704 million yuan, on December 30, 2024, with a repurchase price of 16.88-17.11 yuan per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Joinn Laboratories (06127.HK) spent 1.714 million yuan to repurchase 0.1 million shares of A-shares on December 23.
On December 23, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 23, 2024, it spent 1.714 million yuan to repurchase 0.1 million A-shares, with a repurchase price of 17.1 to 17.18 yuan per share.
Joinn Laboratories will provide Staidson Group with comprehensive pharmaceutical R&D services covering both non-clinical and clinical trial phases.
Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a framework agreement for Staidson's research and development services for 2025, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide the Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases in accordance with the 2025 Staidson research and development services framework agreement. Due to the long-term cooperation with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation, the Director believes that the 2025 Staidson research and development services framework agreement is in line with the company's strategy.
JOINN Laboratories Announces Board Roles and Leadership
JOINN Laboratories Redirects Funds to Boost U.S. Operations
JOINN Laboratories Partners With Staidson for 2025 R&D Services
Joinn Laboratories (06127.HK) has entered into a research and development service agreement with Staidson for the year 2025.
On December 20, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 20, 2024, the company entered into a 2025 research and development service framework agreement with Staidson, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases according to the 2025 Staidson research and development service framework agreement.